Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer|Residual Cancer|Circulating Tumor DNA
Interventions: DRUG: Atezolizumab|DRUG: Sacituzumab govitecan
Sponsor: Dana-Farber Cancer Institute
Collaborators: Genentech, Inc.|Stand Up To Cancer